日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

既往EGFR酪氨酸激酶抑制剂治疗并不影响后续培美曲塞联合铂类药物治疗EGFR突变型晚期初治肺腺癌患者的疗效。

Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Yu, Chong-Jen; Liao, Wei-Yu; Tsai, Chi-Ren; Tsai, Meen-Hsin; Yu, Sung-Liang; Su, Kang-Yi; Chen, Jeremy Jw; Chen, Hsuan-Yu; Chang, Gee-Chen

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma

EGFR突变检测方法对厄洛替尼治疗晚期EGFR野生型肺腺癌患者疗效的影响

Tseng, Jeng-Sen; Wang, Chih-Liang; Huang, Ming-Shyan; Chen, Chung-Yu; Chang, Cheng-Yu; Yang, Tsung-Ying; Tsai, Chi-Ren; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tsai, Meen-Hsin; Yu, Sung-Liang; Su, Kang-Yi; Wu, Chih-Wei; Yang, Cheng-Ta; Chen, Yuh-Min; Chang, Gee-Chen